[Guidelines on atopic dermatitis for Mexico (GUIDAMEX): using the ADAPTE methodology].

Désirée Larenas-Linnemann,Catalina Rincón-Pérez,Jorge A Luna-Pech,Alejandra Macías-Weinmann,Helena Vidaurri-de la Cruz,Elsy M Navarrete-Rodríguez,Blanca E Del Río-Navarro, Liliana Godínez-Alderete,Esther Guevara-Sanginés,José A Ortega-Martell,Mirna E Toledo-Bahena, Bárbara Elizondo-Villareal, Ileana M Madrigal-Beas,Mario Amaya-Guerra, José I Barreras-Salcedo, Leticia Boeta-Ángeles, Armando Campos-Rivera, Martha E Casillas-Guzmán, Mario R Duarte-Abdala,Sara E Espinosa-Padilla, Juan C García-Rodríguez,Minerva Gómez-Flores, Rubén A Gómez-Mendoza, Rosa Ma Del C Lacy-Niebla, Alessandra I Miranda-Aguirre, Claudia Olivares-Nolasco,Ernesto Onuma-Takane,Mariana Pérez-Luna, Carlos L Pliego-Reyes, Ma de Lourdes Rodríguez-Aguilera, María Del Mar Sáez-de Ocariz-Gutiérrez, Arturo Saucedo-Sánchez, Ana B Sotelo-Ocampo, Adriana Ma Valencia-Herrera, Jorge Vázquez-García, Guillermo H Wakida-Kuzunoki, Jacqueline Camarillo-Saavedra, Fernanda A Rodríguez Monroy

Gaceta medica de Mexico(2023)

引用 0|浏览14
暂无评分
摘要
With the advancement of knowledge in relation to the physiopathogenesis of atopic dermatitis (AD), several new therapeutic forms have been developed. There are also new guidelines for self-care. On the other hand, there is still an underdiagnosis of AD in Mexico. Thus, the need was seen to develop a national guide, with a broad base among the different medical groups that care for patients with AD. The Atopic Dermatitis Guidelines for Mexico (GUIDAMEX) was developed with the ADAPTE methodology, with the endorsement and participation of ten national medical societies, from physicians in Primary Healthcare to allergists and dermatologists. Throughout the manuscript, key clinical questions are answered that lead to recommendations and suggestions for the diagnosis of AD (including differential diagnosis with immunodeficiency syndromes), the recognition of comorbidities and complications, non-pharmacological treatment including therapeutic education, treatment of flares and maintenance therapy. The latter encompasses general measures to avoid triggering factors, first-line treatment focussed on repair of the skin barrier, second-line treatment (topical proactive therapy), and third-line phototherapy or systemic treatment, including dupilumab and JAK inhibitors.
更多
查看译文
关键词
Atopic dermatitis,Atopic eczema,Clinical practice guideline,Dupilumab,Flare,JAK inhibitors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要